Nurix Therapeutics (NRIX) closed at $15.30 on November 6, 2026, up 3.1% from the previous close, on volume of 2,724,202 shares (30-day average 3,105,300).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 13, 2026 | Calendar Call Spread | 20-Nov-26 : 15-Jan-27 25 C | 1,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
H.C. Wainwright Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)
TipRanks (Thu, 5-Nov 7:26 AM ET)
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
TipRanks (Wed, 4-Nov 10:41 AM ET)
Jeet Mukherjee Reiterates Buy on Nurix, Maintains $32 Price Target Despite STAT6 Termination
TipRanks (Wed, 4-Nov 8:38 AM ET)
TipRanks (Wed, 4-Nov 8:20 AM ET)
Nurix falls as Sanofi scraps inflammatory disease drug
Seeking Alpha News (Wed, 4-Nov 7:26 AM ET)
At a glance: stocks gapping down premarket
Seeking Alpha News (Wed, 4-Nov 7:11 AM ET)
Sanofi Discontinues Nurix Therapeutics STAT6 Degrader Program
TipRanks (Tue, 3-Nov 4:57 PM ET)
Globe Newswire (Tue, 3-Nov 4:01 PM ET)
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Mon, 12-Oct 4:05 PM ET)
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Nurix Therapeutics trades on the NASDAQ stock market under the symbol NRIX.
As of November 6, 2026, NRIX stock price climbed to $15.30 with 2,724,202 million shares trading.
NRIX has a beta of 1.49, meaning it tends to be more sensitive to market movements. NRIX has a correlation of 0.05 to the broad based SPY ETF.
NRIX has a market cap of $1.67 billion. This is considered a Small Cap stock.
Last quarter Nurix Therapeutics reported $673 million in Revenue and $4.73 earnings per share. This beat revenue expectation by $262 million and exceeded earnings estimates by $.75.
In the last 3 years, NRIX traded as high as $29.56 and as low as $4.96.
The top ETF exchange traded funds that NRIX belongs to (by Net Assets): VTI, ARKG, IWM, XBI, VXF.
NRIX has outperformed the market in the last year with a return of +22.2%, while the SPY ETF gained +10.8%. However, in the most recent history, NRIX shares have underperformed the stock market with its stock returning -39.3% in the last 3 month period and -39.6% for the last 2 week period, while SPY has returned -4.1% and -3.2%, respectively.
NRIX support price is $14.19 and resistance is $15.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRIX shares will trade within this expected range on the day.
